WO2003058191B1 - An intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes - Google Patents

An intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes

Info

Publication number
WO2003058191B1
WO2003058191B1 PCT/IB2002/005834 IB0205834W WO03058191B1 WO 2003058191 B1 WO2003058191 B1 WO 2003058191B1 IB 0205834 W IB0205834 W IB 0205834W WO 03058191 B1 WO03058191 B1 WO 03058191B1
Authority
WO
WIPO (PCT)
Prior art keywords
instrument
sample
error
module
tissue
Prior art date
Application number
PCT/IB2002/005834
Other languages
French (fr)
Other versions
WO2003058191A3 (en
WO2003058191A2 (en
Inventor
Timothy L Ruchti
Christopher Briggs
Thomas B Blank
Alex Lorenz
Mutua Mattu
Marcy Makarewicz
Original Assignee
Sensys Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensys Medical Inc filed Critical Sensys Medical Inc
Priority to AU2002365107A priority Critical patent/AU2002365107A1/en
Publication of WO2003058191A2 publication Critical patent/WO2003058191A2/en
Publication of WO2003058191A3 publication Critical patent/WO2003058191A3/en
Publication of WO2003058191B1 publication Critical patent/WO2003058191B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0062—Arrangements for scanning
    • A61B5/0064—Body surface scanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495—Calibrating or testing of in-vivo probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
    • G01N21/274—Calibration, base line adjustment, drift correction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/004—Artificial life, i.e. computing arrangements simulating life
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

An intelligent system for detecting errors and determining failure modes operates on an absorbance spectrum of in vivo skin tissue. Application of the system results in improved prediction accuracy through rejection of invalid and poor samples. System components include a noninvasive blood glucose meter (101), such as a near IR spectrometer, an error detection system (EDS)(102); a system for diagnosing and mitigating errors (103); and a reporting method (104). In the EDS, a pattern classification engine and hierarchy of levels analyzes, detects and diagnoses instrument, interface and sample errors manifested in the spectrum to determine suitability of an absorbance spectrum for blood glucose measurement. The final component of the system evaluates the error condition, diagnoses the specific mode of failure (if necessary) and reports actions to be taken. Sub-components and levels of the EDS can operate independently of the other system elements to the benefit of a noninvasive glucose measurement system.

Claims

AMENDED CLAIMS[received by the International Bureau on 12 January 2004 (12.01.04); original claims 1-126 replaced by new claims 1-124 (31 pages)]
1. An intelligent system for detecting errors in spectroscopic determination of blood and/or tissue analytes comprising: an apparatus for measuring a spectrum at a selected tissue site on a subject; and an error detection system (EDS), said EDS comprising any of: one or more individual modules, a module embodying at least one of a plurality of methods for detecting errors in spectral measurements; one or more subsystems, a subsystem comprising a plurality of said individual modules having a commonality; and a hierarchic system comprising at least one level, a level comprising one of: at least one subsystem, at least one module, and a combination of at least one subsystem and at least one module; said EDS further comprising an error manager for coordinating said EDS by keeping a record of generated errors; wherein said intelligent system detects conditions unsuitable for analyte determination.
2. The system of Claim 1 , wherein said modules output an acceptability measure, each module having a range of acceptability specified for its associated acceptability measure, wherein said ranges of acceptability are based on a set of exemplary samples, the set containing both erroneous measurements of known origin and valid measurements; and wherein an acceptability measure outside of its associated range of acceptability constitutes an error.
3. The system of Claim 1 , wherein said apparatus for measuring a spectrum comprises a spectrometer instrument.
4. The system of Claim 1 , wherein said analyte comprises glucose.
5. The system of Claim 1 , wherein measurement is any of noninvasive and in vivo.
6. The system of Claim 1 , further comprising a preprocessing and feature extraction system.
7. The system of Claim 6, wherein said preprocessing and feature extraction system comprises: means for low-level processing of raw intensity spectra, spectra including sample spectra and reference spectra; means for averaging processed intensity spectra; means for calculating an absorbance spectrum from said processed intensity spectra; means for preprocessing said absorbance spectrum; means for extracting features from a preprocessed absorbance spectrum; a tissue template set, the tissue template comprising a set of measurements taken at onset of a measurement period; and a calibration model, said calibration model applied to any of said preprocessed absorbance spectrum and extracted features to measure said analyte, said calibration model also applied to estimate relative precision of a measurement and/or determine certainty of a measurement in view of past measurements.
104
8. The system of Claim 7, wherein low-level processing includes subtraction of an electrical offset from said raw intensity spectra.
9. The system of Claim 7, wherein averaging includes any of: simple average calculation; and robust estimation of mean intensity at each wavelength.
10. The system of Claim 7, wherein said absorbance spectrum comprises a specific set of wavelengths in the near IR region that has been optimized for feature extraction and measurement.
11. The system of Claim 7, wherein preprocessing includes any of: scaling; normalizing; smoothing; derivatizing; filtering; and transformations that attenuate noise and instrumental variation without unduly affecting signal of interest.
12. The system of Claim 7, wherein said features include any of: simple features, comprising values of a processed spectral measurement at which slope equals zero; derived features, comprising additional features derived from simple features through mathematical transformation; and abstract features developed through linear and/or nonlinear transformations of said oreDrocessed snectrum.
105
13. The system of Claim 12, wherein simple features include any of: critical points; normalization points; fat band points; protein band points; and water band points.
14. The system of Claim 12, wherein derived features are mathematically derived from said critical, normalization, fat band, protein band, and water band points.
15. The system of Claim 12, wherein abstract features do not have a specific interpretation related to a physical system, abstract features including scores from a principal components analysis.
16. The system of Claim 7, wherein said tissue template set includes any of: intensity spectra for sample and reference; an absorbance spectrum; a preprocessed absorbance spectrum; and a set of extracted features.
17. The system of Claim 1 , said intelligent system further comprising a state classification and rule-based decision system.
106
18. The system of Claim 17, wherein said state classification and rule- based decision system comprises: means for collecting acceptability measures from said modules; optionally, means for normalizing said acceptability measures; a classifier, wherein said classifier determines at least one operating state for each of said levels; and a rule-based decision engine, wherein a decision is made regarding acceptability of an analyte measurement based on said determined operating states.
19. The system of Claim 18, wherein said classifier is developed from a data set of exemplary spectral measurements from a representative population sample.
20. The system of Claim 19, wherein classes are defined by assigning said measurements from said data set to classes.
21. The system of Claim 19, wherein class definition employs a supervised approach, wherein classes are defined through known differences in the data.
22. The system of Claim 19, wherein class definition employs an unsupervised approach, wherein said acceptability measures are used to explore and develop clusters of the data in feature space, so that within cluster homogeneity and between cluster separation is optimized.
23. The system of Claim 22, wherein a large set of samples from a multiplicity of subjects is used to create a database, the database including acceptability measures, measurements, and reference measurements.
107
24. The system of Claim 23, wherein acceptability measures are sorted according to level of sophistication.
25. The system of Claim 24, wherein an abstract factor analysis is performed to account for redundancy of information presented by said acceptability measures; and wherein a cluster analysis is performed to identify classes, said classes constituting states, that are associated with various levels of measurement error.
26. The system of Claim 25, wherein states are combined to provide an error diagnosis.
27. The system of Claim 22, wherein said data set is created through introduction of errors associated with defined categories, and wherein a statistical classifier is used to map said acceptability measures to a final decision.
28. The system of Claim 22, wherein said classifier is designed by determining an optimal mapping from feature space to a class estimate that minimizes misclassifications.
29. The system of Claim 22, wherein statistically based class definitions provide crisp class definitions.
30. The system of Claim 19, wherein class assignment and decisions are based on fuzzy set theory.
108
31. The system of Claim 30, wherein membership in fuzzy sets is defined by a continuum of grades and a set of membership functions that map feature space into an interval for each class, wherein assigned membership grade represents a degree of class membership, so that a sample can simultaneously be a member of more than one class.
32. The system of Claim 1 , wherein said modules include any of: an online error check module; an instrument error-detection module; an instrument QC (quality control)-checking module; a signal-processing module; a sampling error-detection module; a spectral anomaly-detection module; surface contact error-detection module; a hydration-checking module; a sample variation-detection module; a sample transient-detection module a patient skin temperature-measuring module a sample consistency-assessment module; a sample stability-assessment module a tissue transient-detection module; a skin temperature transient-detection module; a data consistency module; a sample structure variation-detection module; an instrument drift-monitoring module; an instrument stability-monitoring module;
109 a classification module; a calibration set-comparison module; an instrument operation-comparison module; a measurement precision-estimation module; a measurement range-assessment module; and an expected value-prediction module.
33. The system of Claim 32, wherein subsystems are defined according to sophistication of included modules, said subsystems including any of: a low-level subsystem; a mid-level subsystem; and a high-level subsystem.
34. The system of Claim 33, wherein said low-level subsystem includes modules for testing data immediately after collection of reference and sample spectra, said spectra comprising intensity spectra
35. The system of Claim 34, wherein testing is based on acceptability specifications for noninvasive glucose measurement, and wherein an action resulting from deviation from a specified level of acceptability includes any of: rejection of a collected spectrum; rejection of a tissue sample; and generation of an instrument malfunction error.
36. The system of Claim 33, wherein said low-level subsystem includes any of:
no the online error check module; the instrument error detection module; the instrument QC-checking module; the signal processing module; and the sampling error detection module.
37. The system of Claim 33, wherein a system manager inputs instrument performance specifications and target spectra for each type of material to be scanned to said low-level subsystem.
38. The system of Claim 37, wherein said specifications include any of: noise limits; minimum operating temperature limits; maximum signal levels, wavelength accuracy limits; and precision limits.
39. The system of Claim 33, wherein said mid-level subsystem optionally comprises a plurality of sublevels, said sublevels corresponding to type of information necessary for analysis.
40. The system of Claim 33, wherein said mid-level uses a tissue template to determine if instrument performance and/or a sampled tissue volume have changed relative to an earlier time.
41. The system of Claim 33, wherein said mid-level includes any of: the spectral anomaly-detection module;
111 the surface contact error-detection module; the hydration-checking module; the sample variation-detection module; the sample transient-detection module the patient skin temperature-measuring module the sample consistency-assessment module; the sample stability-assessment module the tissue transient-detection module; the skin temperature transient-detection module; the data consistency module; the sample structure variation-detection module; the instrument drift-monitoring module; the instrument stability-monitoring module; and the instrument performance-monitoring module.
42. The system of Claim 33, wherein actions taken by said mid-level subsystem include any of: instrument maintenance; recollect tissue template; sample rejection; and instrument QC check.
43. The system of Claim 33, wherein said high-level subsystem relies on: a calibration model and parameters relating to the calibration model; a patient database; oatient historv:
112 a tissue template; and measurement specifications common to all instruments and all patients.
44. The system of Claim 33, wherein said high-level subsystem includes any of: the classification module; the calibration set-comparison module; the instrument operation-comparison module; the measurement precision-estimation module; the measurement range-assessment module; and the expected value-prediction module.
45. The system of Claim 33, wherein actions taken by said high-level subsystem include any of: change calibration model; recalibrate patient; instrument failure; invalid glucose measurement; instrument maintenance; recollect tissue template; sample rejection; and instrument QC check.
46. The system of Claim 33, wherein levels of said hierarchic system receive and inherit information from lower levels.
47. The system of Claim 46, wherein errors generated at each level are inherited by succeeding levels for error diagnosis until a critical error is encountered.
48. The system of Claim 46, wherein a composite of acceptability measures from each module is input to a state classification and decision system to diagnose specific source of said error.
49. The system of Claim 48, further comprising a database of corrective instructions.
50. A method for detecting errors in spectroscopic measurement of blood and/or tissue analytes comprising the steps of: measuring at least one spectrum at a selected tissue site on a subject; applying one more individual methods for detecting errors in spectral measurements to said measured spectrum, wherein said methods are implemented individually, in subsystems according to a commonality among selected methods, or in a hierarchy wherein a level of said hierarchy implements any of: at least one method, at least one subsystem, and a combination of at least one method and at least one subsystem; collecting output of said methods; detecting conditions inconsistent with analyte determination based on said output; reporting a decision regarding acceptability of a measurement; and keeping a record of generated errors.
51. The method of Claim 50, further comprising the steps of: outputting an acceptability measure by each method; and
114 defining a range of acceptability for each acceptability measure wherein ranges of acceptability are based on a set of exemplary samples, the set including both erroneous measurements of known origin and valid measurements; and generating an error when an acceptability measure is outside of its associated range of acceptability.
52. The method of Claim 51 , wherein said analyte comprises glucose.
53. The method of Claim 51 , further comprising the step of: processing raw spectra, spectra including sample spectra and reference spectra; averaging processed intensity spectra; calculating an absorbance spectrum from said processed intensity spectra; preprocessing said absorbance spectrum; extracting features from a preprocessed absorbance spectrum; generating a tissue template set, the tissue template comprising a set of measurements taken at onset of a measurement period; and providing a calibration model, said calibration model applied to any of said preprocessed absorbance spectrum and extracted features to measure said analyte, said calibration model also applied to estimate relative precision of a measurement and/or determine certainty of a measurement in view of past measurements.
54. The method of Claim 53, wherein processing raw spectra comprises: subtracting an electrical offset from said raw intensity spectra.
115
55. The method of Claim 53, wherein averaging comprises the steps of: calculating a simple average; and producing a robust estimation of mean intensity at each wavelength.
56. The method of Claim 53, wherein said absorbance spectrum comprises a specific set of wavelengths in the near IR region that has been optimized for feature extraction and measurement.
57. The method of Claim 53, wherein preprocessing comprises: scaling; normalizing; smoothing; derivatizing; filtering; and transformations that attenuate noise and instrumental variation without unduly affecting signal of interest.
58. The method of Claim 53, wherein said features include any of: simple features, comprising values of a processed spectral measurement at which slope equals zero; derived features, comprising additional features derived from simple features through mathematical transformation; and abstract features developed through linear and/or nonlinear transformations of said preprocessed spectrum.
59. The method of Claim 58, wherein simple features include any of: critical points;
116 normalization points; fat band points; protein band points; and water band points.
60. The method of Claim 58, wherein derived features are mathematically derived from said critical, normalization, fat band, protein band, and water band points.
61. The method of Claim 58, wherein abstract features do not have a specific interpretation related to a physical system, abstract features including scores from a principal components analysis.
62. The method of Claim 53, wherein said tissue template set includes any of: intensity spectra for sample and reference; an absorbance spectrum; a preprocessed absorbance spectrum; and a set of extracted features.
63. The method of Claim 50, wherein said outputs constitute acceptability measures, and wherein said step of collecting said outputs comprises: inputting said acceptability measures to a state classification and rule-based decision system.
64. The method of Claim 63, further comprising the step of: optionally, normalizing said acceptability measures;
117 determining at least one operating state for each of said levels; and making a decision regarding acceptability of an analyte measurement based on said determined operating states.
65. The method of Claim 64, wherein the step of determining at least one operating state for each of said levels comprises the step of: providing a classifier, wherein said classifier is developed from a data set of exemplar spectral measurements from a representative population sample.
66. The method of Claim 65, the step of determining at least one operating state further comprising the step of: defining classes by assigning said measurements from said data set to classes.
67. The method of Claim 66, wherein the step of defining classes comprises: defining classes through known differences in the data, based on a supervised approach.
68. The method of Claim 66, wherein the step of defining classes comprises: exploring and developing clusters of the data in feature space, wherein class definition employs an unsupervised approach, wherein said acceptability measures are used to, so that within cluster homogeneity and between cluster separation is optimized.
118
69. The method of Claim 68, wherein a large set of samples from a multiplicity of subjects is used to create a database, the database including acceptability measures, measurements, and reference measurements.
70. The method of Claim 68, wherein acceptability measures are sorted according to level of sophistication.
71. The method of Claim 68, wherein the step of defining classes further comprises: performing an abstract factor analysis to account for redundancy of information presented by said acceptability measures; and performing a cluster analysis to identify classes, said classes constituting states, associated with various levels of measurement error.
72. The method of Claim 71 , further comprising the step of combining states to provide an error diagnosis.
73. The method of Claim 65, wherein said data set is created through introduction of errors associated with defined categories, and wherein a statistical classifier is used to map said acceptability measures to a final decision.
74. The method of Claim 73, wherein said classifier is designed by determining an optimal mapping from feature space to a class estimate that minimizes misclassifications.
75. The method of Claim 65, wherein statistically based class definitions provide crisp class definitions.
119
76. The method of Claim 65, wherein class assignment and decisions are based on fuzzy set theory.
77. The method of Claim 76, wherein membership in fuzzy sets is defined by a continuum of grades and a set of membership functions that map feature space into an interval for each class, wherein assigned membership grade represents a degree of class membership, so that a sample can simultaneously be a member of more than one class.
78. The method of Claim 50, wherein said individual methods include any of: an online error check method; an instrument error-detection method; an instrument QC (quality control)-checking method; a signal-processing method; a sampling error-detection method; a spectral anomaly-detection method; surface contact error-detection method; a hydration-checking method; a sample variation-detection method; a sample transient-detection method; a patient skin temperature-measuring method; a sample consistency-assessment method; a sample stability-assessment method; a tissue transient-detection method; a skin temperature transient-detection method; a data consistencv method:
120 a sample structure variation-detection method; an instrument drift-monitoring method; an instrument stability-monitoring method; an instrument performance-monitoring method; a classification method; a calibration set-comparison method; an instrument operation-comparison method; a measurement precision-estimation method; a measurement range-assessment method; and an expected value-prediction method,
79. The method of Claim 78, wherein said online error check method comprises the step of: determining whether proper material has been scanned and whether material characteristics are similar to previously set standards.
80. The method of Claim 78, wherein said instrument error-detection method comprises the step of: detecting errors based on a series of tests that evaluate signal levels compared to a target range at particular wavelengths indicative of failure modes.
81. The method of Claim 78, wherein failure modes include any of: illumination system failure; excessive instrument temperature; damaged illumination/detection elements; and excessive changes in light intensity.
121
82. The method of Claim 78, wherein the instrument QC method comprises the step of: determining if the instrument is operating according to instrument specifications and reporting an error if not.
83. The method of Claim 78, wherein said specifications include specifications for any of: instrument noise (at each wavelength and overall); peak signal level; and x-axis variation.
84. The method of Claim 78, wherein said signal-processing method comprises any of the steps of: applying baseline correction; applying ensemble averaging applying wavelength standardization; applying finite impulse response filtering (FIR); differentiating; applying multiplicative scatter correction; applying standard normal transformation; and calculating absorbance; wherein all scanned materials are processed into a set of spectra that can be used to perform error detection and measure blood glucose.
85. The method of Claim 78, wherein said sampling error-detection method comprises the step of:
122 detecting gross sampling errors, gross sampling errors including any of: lifting or moving body part bearing measurement site during scanning; moving a reference during scanning; and improper application of a coupling medium.
86. The method of Claim 78, wherein said spectral anomaly detection method comprises the step of: detecting changes in relative absorbance of constituents at various depths corresponding to modification of a sampled tissue volume.
87. The method of Claim 78, wherein said surface contact error detection method comprises the steps of: extracting spectral features related to surface contact and comparing said extracted features to related features from a tissue template spectrum, wherein an error condition results if surface contact deviates significantly from said tissue template or from an a priori level.
88. The applying of Claim 78, wherein said hydration-checking method comprises the steps of: extracting spectral features related to sample hydration; comparing said extracted features to features from a tissue template and previously calculated features; and reporting an error condition if patient's hydration has changed significantly from that of tissue template.
89. The method of Claim 78, wherein said sample variation-detection
123 detecting mechanical distortion of an optically sampled tissue volume, wherein extracted features from a sample spectrum are compared to features from a tissue template by means of a distance measure, and reporting an error if said sample spectrum exceeds a pre-set limit.
90. The method of Claim 78, wherein said sample transient-detection method comprises the step of: detecting rapid changes in coupling between a patient interface module and sample site, or rapid change in the sample by comparing extracted features with a previously established library representing a plurality of error conditions, error conditions including: arm movement while scanning; perspiration; excessive pressure; poor patient-instrument coupling; tissue distortion; tissue heating; rapid changes in patient physiology; fluid displacement in the tissue; and poor sampling conditions.
91. The method of Claim 78, wherein said patient skin temperature- measuring method comprises either of the steps of: detecting patient skin temperature through a direct measurement with a skin temperature probe; or detecting patient skin temperature spectroscopically based on a predetermined skin temperature calibration model;
124 wherein the skin temperature is compared to skin temperature associated with a tissue template, and temperatures that vary from a target range produce an error condition.
92. The method of Claim 78, wherein said sample consistency- assessment method comprises the step of: comparing a sample spectrum with prior patient scans and calculating similarity; wherein an error condition results if the sample spectrum differs substantially from the prior scans.
93. The method of Claim 78, wherein said sample stability-assessment module comprises the step of: comparing level of analyte marker bands with pre-set limits by comparing a processed sample spectrum with a tissue template spectrum over a selected wavelength range and calculating similarity between the two spectra; wherein an error condition results if the sample spectrum differs substantially from the tissue template.
94. The method of Claim 78, wherein said tissue transient-detection method comprises the step of: examining time history of sample spectra features related to any of: changes in physiological state; changes in local tissue morphology; and patient-instrument coupling errors; wherein an error condition occurs if range and time-related correlation of a feature exceeds a predetermined limit.
125
95. The method of Claim 78, wherein said skin temperature transient- detection method comprises the step of: comparing range and time correlation of measured skin temperature over samples collected subsequent to collecting a tissue template, wherein a sample that is either out of range or that displays a unidirectional temperature change results in an error condition.
96. The method of Claim 78, wherein said data consistency method comprises the step of: comparing sample spectra with historical data; wherein an error condition results if variability within the sample spectrum is inconsistent with said historical data.
97. The method of Claim 78, wherein said sample structure variation- detection method comprises the step of: comparing a tissue fingerprint of a newly collected sample spectrum with that of an original stored tissue template, said tissue fingerprint comprising a plurality of distinct features related to analyte absorption; wherein an error condition results if the newly collected sample spectrum differs substantially from said tissue template, an error indicating a gross change in sampled tissue volume.
98. The method of Claim 78, wherein said instrument drift-monitoring method comprises the step of: comparing performance parameters with data collected with a tissue template; wherein an error condition results if an instrument is outside of normal instrument operating procedures.
126
99. 1 he method of Claim 78, wherein said instrument stability-monitoring method comprises the step of: comparing sample spectra with data from a history file containing instrument parameters, parameters including any of RMS (root mean squared) noise, wavelength shift and signal intensity; wherein an error condition occurs if instrument performance has changed over a short time period.
100. The method of Claim 78, wherein said instrument performance- monitoring method comprises the step of: predicting potential instrument-related failure based on monitoring changes in any of instrument noise, temperatures, wavelength stability, and signal intensity over life of the instrument.
101. The method of Claim 78, wherein said classification method comprises the step of: determining a suitable patient class for calibration on the basis of a calibration database; wherein sample spectral falling outside a classified set are classed as outliers so that an error conditions results.
102. The method of Claim 78, wherein said calibration set-comparison method comprises the step of: comparing a sample spectrum with a calibration set using any of feature extraction and cluster analysis to determine consistency of the sample spectrum with spectral data used to generate a calibration model, wherein spectra falling outside a range of calibration create an error condition.
127
103. The method of Claim 78, wherein said instrument operation- comparison method comprises the step of: comparing operational state of the instrument with similar instruments, including an instrument used to collect calibration data, wherein history information from said similar instruments is pooled to compare characteristics of the instrument with the similar instruments.
104. The method of Claim 78, wherein said measurement precision- estimation method comprises the step of: applying a calibration model to each of a set of tissue absorbance replicates to compare any of range, trend and standard deviation of glucose measurements based on said replicates with a maximum acceptable value; wherein measurements exceeding said value are rejected, so that a confidence estimate of a final, averaged glucose measurement is produced.
105. The method of Claim 78, wherein said measurement range- assessment method comprises the step of: averaging glucose measurements associated with a set of replicate spectral scans to yield a final glucose measurement; wherein an error condition results if said final measurement is outside a preset range.
106. The method of Claim 78, wherein said expected value-prediction method comprises the steps of: applying a prediction module to predict erroneous glucose measurements, wherein said prediction model uses a time series of past glucose measurements to extrapolate a future prediction; and comparing said predication with a measurement based on a newly acquired sample spectrum;
128 wherein an error results if a large discrepancy exists between the measurement from the newly acquired spectrum and the prediction, where the prediction has a high degree of certainty.
107. The method of Claim 78, wherein subsystems are defined according to sophistication of included methods, said subsystems including any of: a low-level subsystem; a mid-level subsystem; and a high-level subsystem.
108. The method of Claim 107, wherein said low-level subsystem includes methods for testing data immediately after collection of reference and sample spectra, said spectra comprising intensity spectra
109. The method of Claim 107, wherein testing is based on acceptability specifications for noninvasive glucose measurement, and wherein an action resulting from deviation from a specified level of acceptability includes any of: rejection of a collected spectrum; rejection of a tissue sample; and generation of an instrument malfunction error.
110. The method of Claim 107, wherein said low-level subsystem includes any of: the online error check method; the instrument error detection method; the instrument QC-checking method; the signal processing method; and
129 the sampling error detection method.
11 1. The method of Claim 107, wherein a system manager inputs instrument performance specifications and target spectra for each type of material to be scanned to said low-level subsystem.
112. The method of Claim 111 , wherein said specifications include any of: noise limits; minimum operating temperature limits; maximum signal levels, wavelength accuracy limits; and precision limits.
113. The method of Claim 107, wherein actions taken by said low-level subsystem include any of: sample rejection; and instrument QC check.
114. The method of Claim 107, wherein said mid-level subsystem comprises a plurality of sublevels, said sublevels corresponding to type of information necessary for analysis.
1 15. The method of Claim 107, wherein said mid-level uses a tissue template to determine if instrument performance and/or a sampled tissue volume have changed relative to an earlier time.
116. The system of Claim 107, wherein said mid-level includes any of:
130 the spectral anomaly-detection method; the surface contact error-detection method; the hydration-checking method; the sample variation-detection method; the sample transient-detection method; the patient skin temperature-measuring method; the sample consistency-assessment method; the sample stability-assessment method; the tissue transient-detection method; the skin temperature transient-detection method; the data consistency method; the sample structure variation-detection method; the instrument drift-monitoring method; the instrument stability-monitoring method; and the instrument performance-monitoring method.
117. The method of Claim 107, wherein actions taken by said mid-level subsystem include any of: instrument maintenance; recollect tissue template; sample rejection; and instrument QC check.
118. The method of Claim 107, wherein said high-level subsystem relies on: a calibration model and parameters relating to the calibration model;
131 a patient database; patient history; a tissue template; and measurement specifications common to all instruments and all patients.
119. The method of Claim 107, wherein said high-level subsystem includes any of: the classification method; the calibration set-comparison method; the instrument operation-comparison method; the measurement precision-estimation method; the measurement range-assessment method; and the expected value-prediction method.
120. The method of Claim 107, wherein actions taken by said high-level subsystem include any of: change calibration model; recalibrate patient; instrument failure; invalid glucose measurement; instrument maintenance; recollect tissue template; sample rejection; and instrument QC check.
132
121. The method of Claim 107, wherein levels of said hierarchic system receive and inherit information from lower levels.
122. The method of Claim 121 , wherein errors generated at each level are inherited by succeeding levels for error diagnosis until a critical error is encountered.
123. The method of Claim 121 , wherein a composite of acceptability measures from each module is input to a state classification and decision system to diagnose specific source of said error.
124. The method of Claim 123, further comprising the step of: providing corrective instructions from a database of corrective instructions.
133
PCT/IB2002/005834 2001-08-03 2002-08-05 An intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes WO2003058191A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002365107A AU2002365107A1 (en) 2001-08-03 2002-08-05 An intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31003301P 2001-08-03 2001-08-03
US60/310,033 2001-08-03
US10/211,478 2002-08-01
US10/211,478 US6788965B2 (en) 2001-08-03 2002-08-01 Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes

Publications (3)

Publication Number Publication Date
WO2003058191A2 WO2003058191A2 (en) 2003-07-17
WO2003058191A3 WO2003058191A3 (en) 2004-02-26
WO2003058191B1 true WO2003058191B1 (en) 2004-04-01

Family

ID=26906177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005834 WO2003058191A2 (en) 2001-08-03 2002-08-05 An intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes

Country Status (3)

Country Link
US (1) US6788965B2 (en)
AU (1) AU2002365107A1 (en)
WO (1) WO2003058191A2 (en)

Families Citing this family (405)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7206623B2 (en) * 2000-05-02 2007-04-17 Sensys Medical, Inc. Optical sampling interface system for in vivo measurement of tissue
US7519406B2 (en) * 2004-04-28 2009-04-14 Sensys Medical, Inc. Noninvasive analyzer sample probe interface method and apparatus
US20070179367A1 (en) * 2000-05-02 2007-08-02 Ruchti Timothy L Method and Apparatus for Noninvasively Estimating a Property of an Animal Body Analyte from Spectral Data
US20060211931A1 (en) * 2000-05-02 2006-09-21 Blank Thomas B Noninvasive analyzer sample probe interface method and apparatus
US7606608B2 (en) * 2000-05-02 2009-10-20 Sensys Medical, Inc. Optical sampling interface system for in-vivo measurement of tissue
US7243117B2 (en) * 2001-02-07 2007-07-10 Fdk Corporation Random number generator and probability generator
US7756558B2 (en) * 2004-05-24 2010-07-13 Trutouch Technologies, Inc. Apparatus and methods for mitigating the effects of foreign interferents on analyte measurements in spectroscopy
US20040172225A1 (en) * 2001-06-01 2004-09-02 Prosanos Corp. Information processing method and system for synchronization of biomedical data
WO2002099568A2 (en) * 2001-06-01 2002-12-12 Prosanos Corporation Information processing method for disease stratification and assessment of disease progressing
US6697658B2 (en) 2001-07-02 2004-02-24 Masimo Corporation Low power pulse oximeter
US7355512B1 (en) 2002-01-24 2008-04-08 Masimo Corporation Parallel alarm processor
EP1499231A4 (en) * 2002-03-08 2007-09-26 Sensys Medical Inc Compact apparatus for noninvasive measurement of glucose through near-infrared spectroscopy
US7697966B2 (en) * 2002-03-08 2010-04-13 Sensys Medical, Inc. Noninvasive targeting system method and apparatus
US20070149868A1 (en) * 2002-03-08 2007-06-28 Blank Thomas B Method and Apparatus for Photostimulation Enhanced Analyte Property Estimation
US8718738B2 (en) 2002-03-08 2014-05-06 Glt Acquisition Corp. Method and apparatus for coupling a sample probe with a sample site
US8504128B2 (en) * 2002-03-08 2013-08-06 Glt Acquisition Corp. Method and apparatus for coupling a channeled sample probe to tissue
US20050054908A1 (en) * 2003-03-07 2005-03-10 Blank Thomas B. Photostimulation method and apparatus in combination with glucose determination
US6850788B2 (en) 2002-03-25 2005-02-01 Masimo Corporation Physiological measurement communications adapter
US7259906B1 (en) 2002-09-03 2007-08-21 Cheetah Omni, Llc System and method for voice control of medical devices
EP2322798A1 (en) 2002-10-09 2011-05-18 Abbott Diabetes Care Inc. Device and method for delivering medical fluids using a shape memory alloy
US7727181B2 (en) 2002-10-09 2010-06-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
US7993108B2 (en) 2002-10-09 2011-08-09 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US8771183B2 (en) * 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US6920345B2 (en) 2003-01-24 2005-07-19 Masimo Corporation Optical sensor including disposable and reusable elements
US20040204868A1 (en) * 2003-04-09 2004-10-14 Maynard John D. Reduction of errors in non-invasive tissue sampling
US7679407B2 (en) 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US7722536B2 (en) * 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
WO2005006984A1 (en) 2003-07-22 2005-01-27 Kabushiki Kaisha Toshiba Biological information measurement device
US7500950B2 (en) 2003-07-25 2009-03-10 Masimo Corporation Multipurpose sensor port
US8060173B2 (en) 2003-08-01 2011-11-15 Dexcom, Inc. System and methods for processing analyte sensor data
US8626257B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US7925321B2 (en) 2003-08-01 2011-04-12 Dexcom, Inc. System and methods for processing analyte sensor data
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US7591801B2 (en) * 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US8676287B2 (en) 2003-08-01 2014-03-18 Dexcom, Inc. System and methods for processing analyte sensor data
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
WO2005020798A2 (en) * 2003-08-27 2005-03-10 Datex-Ohmeda, Inc. Multi-domain motion estimation and plethysmographic recognition using fuzzy neural-nets
US20070234300A1 (en) * 2003-09-18 2007-10-04 Leake David W Method and Apparatus for Performing State-Table Driven Regression Testing
US7299082B2 (en) * 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US7483729B2 (en) 2003-11-05 2009-01-27 Masimo Corporation Pulse oximeter access apparatus and method
US8532730B2 (en) 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
US7657443B2 (en) * 2003-12-19 2010-02-02 Carefusion 303, Inc. Intravenous medication harm index system
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
EP1722676B1 (en) 2004-03-08 2012-12-19 Masimo Corporation Physiological parameter system
US20080033275A1 (en) * 2004-04-28 2008-02-07 Blank Thomas B Method and Apparatus for Sample Probe Movement Control
US8868147B2 (en) * 2004-04-28 2014-10-21 Glt Acquisition Corp. Method and apparatus for controlling positioning of a noninvasive analyzer sample probe
US20060281068A1 (en) * 2005-06-09 2006-12-14 Chemimage Corp. Cytological methods for detecting a disease condition such as malignancy by Raman spectroscopic imaging
US7697576B2 (en) * 2004-05-05 2010-04-13 Chem Image Corporation Cytological analysis by raman spectroscopic imaging
US20060010098A1 (en) 2004-06-04 2006-01-12 Goodnow Timothy T Diabetes care host-client architecture and data management system
JP4756675B2 (en) * 2004-07-08 2011-08-24 インターナショナル・ビジネス・マシーンズ・コーポレーション System, method and program for predicting computer resource capacity
US7076399B2 (en) * 2004-07-19 2006-07-11 Baylis Medical Company Inc. Medical generator with hierarchical error logic
US7596469B2 (en) * 2004-07-19 2009-09-29 Baylis Medical Company Inc. Method and apparatus for prioritizing errors in a medical treatment system
US7822452B2 (en) 2004-08-11 2010-10-26 Glt Acquisition Corp. Method for data reduction and calibration of an OCT-based blood glucose monitor
US20100331646A1 (en) * 2009-06-30 2010-12-30 Abbott Diabetes Care Inc. Health Management Devices and Methods
US9636450B2 (en) * 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US7722537B2 (en) * 2005-02-14 2010-05-25 Optiscan Biomedical Corp. Method and apparatus for detection of multiple analytes
EP1852101B1 (en) * 2005-02-16 2015-09-02 Hitachi Medical Corporation Biophoton measuring instrument
US8190223B2 (en) 2005-03-01 2012-05-29 Masimo Laboratories, Inc. Noninvasive multi-parameter patient monitor
US20060217602A1 (en) * 2005-03-04 2006-09-28 Alan Abul-Haj Method and apparatus for noninvasive targeting
WO2006102412A2 (en) 2005-03-21 2006-09-28 Abbott Diabetes Care, Inc. Method and system for providing integrated medication infusion and analyte monitoring system
US7467065B2 (en) * 2005-05-02 2008-12-16 Home Diagnostics, Inc. Computer interface for diagnostic meter
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US7620437B2 (en) 2005-06-03 2009-11-17 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US8253936B2 (en) * 2008-08-08 2012-08-28 Chemimage Corporation Raman characterization of transplant tissue
CA2616402A1 (en) 2005-07-26 2007-02-01 Bayer Healthcare Llc Method and system for checking an electromechanical biosensor
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US8880138B2 (en) 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
US7962188B2 (en) 2005-10-14 2011-06-14 Masimo Corporation Robust alarm system
US7583190B2 (en) 2005-10-31 2009-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7519253B2 (en) 2005-11-18 2009-04-14 Omni Sciences, Inc. Broadband or mid-infrared fiber light sources
US8182443B1 (en) 2006-01-17 2012-05-22 Masimo Corporation Drug administration controller
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US8344966B2 (en) * 2006-01-31 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing a fault tolerant display unit in an electronic device
US7981034B2 (en) 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US8219172B2 (en) 2006-03-17 2012-07-10 Glt Acquisition Corp. System and method for creating a stable optical interface
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US10188348B2 (en) 2006-06-05 2019-01-29 Masimo Corporation Parameter upgrade system
US8206296B2 (en) 2006-08-07 2012-06-26 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
US8457707B2 (en) 2006-09-20 2013-06-04 Masimo Corporation Congenital heart disease monitor
US8840549B2 (en) 2006-09-22 2014-09-23 Masimo Corporation Modular patient monitor
US7880626B2 (en) 2006-10-12 2011-02-01 Masimo Corporation System and method for monitoring the life of a physiological sensor
US8280473B2 (en) 2006-10-12 2012-10-02 Masino Corporation, Inc. Perfusion index smoother
US8255026B1 (en) 2006-10-12 2012-08-28 Masimo Corporation, Inc. Patient monitor capable of monitoring the quality of attached probes and accessories
US9861305B1 (en) 2006-10-12 2018-01-09 Masimo Corporation Method and apparatus for calibration to reduce coupling between signals in a measurement system
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
WO2008073855A2 (en) 2006-12-09 2008-06-19 Masimo Corporation Plethysmograph variability processor
US8652060B2 (en) 2007-01-20 2014-02-18 Masimo Corporation Perfusion trend indicator
US20080199894A1 (en) 2007-02-15 2008-08-21 Abbott Diabetes Care, Inc. Device and method for automatic data acquisition and/or detection
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8357090B2 (en) * 2007-03-09 2013-01-22 Covidien Lp Method and apparatus for estimating water reserves
CA2683953C (en) 2007-04-14 2016-08-02 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683959C (en) 2007-04-14 2017-08-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683721C (en) 2007-04-14 2017-05-23 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
EP2146625B1 (en) 2007-04-14 2019-08-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
ES2817503T3 (en) 2007-04-14 2021-04-07 Abbott Diabetes Care Inc Procedure and apparatus for providing data processing and control in a medical communication system
US8374665B2 (en) 2007-04-21 2013-02-12 Cercacor Laboratories, Inc. Tissue profile wellness monitor
US20080281179A1 (en) * 2007-05-08 2008-11-13 Abbott Diabetes Care, Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US20080278332A1 (en) * 2007-05-08 2008-11-13 Abbott Diabetes Care, Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
EP2156684A4 (en) * 2007-05-14 2012-10-24 Abbott Diabetes Care Inc Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8597190B2 (en) 2007-05-18 2013-12-03 Optiscan Biomedical Corporation Monitoring systems and methods with fast initialization
US8026382B2 (en) * 2007-05-18 2011-09-27 Heidi Kay Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
WO2008154312A1 (en) 2007-06-08 2008-12-18 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8617069B2 (en) * 2007-06-21 2013-12-31 Abbott Diabetes Care Inc. Health monitor
JP5680960B2 (en) 2007-06-21 2015-03-04 アボット ダイアベティス ケア インコーポレイテッドＡｂｂｏｔｔ Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｉｎｃ． Health care device and method
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US20090063402A1 (en) * 2007-08-31 2009-03-05 Abbott Diabetes Care, Inc. Method and System for Providing Medication Level Determination
US20090076773A1 (en) * 2007-09-14 2009-03-19 Texas Tech University Method for identifying unmeasured disturbances in process control test data
US9452258B2 (en) 2007-10-09 2016-09-27 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US20090164190A1 (en) * 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Physiological condition simulation device and method
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
WO2009111542A2 (en) 2008-03-04 2009-09-11 Glucolight Corporation Methods and systems for analyte level estimation in optical coherence tomography
JP5575752B2 (en) 2008-05-02 2014-08-20 マシモ コーポレイション Monitor configuration system
JP2011519684A (en) 2008-05-05 2011-07-14 マシモ コーポレイション Pulse oximeter system with electrical disconnect circuit
US8591410B2 (en) 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8924159B2 (en) 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8577431B2 (en) 2008-07-03 2013-11-05 Cercacor Laboratories, Inc. Noise shielding for a noninvasive device
WO2010009172A1 (en) 2008-07-14 2010-01-21 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US8630691B2 (en) 2008-08-04 2014-01-14 Cercacor Laboratories, Inc. Multi-stream sensor front ends for noninvasive measurement of blood constituents
US8416405B2 (en) * 2008-08-08 2013-04-09 Chemimage Corporation Raman chemical imaging of implantable drug delivery devices
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US8622988B2 (en) * 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US8734422B2 (en) * 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
SE532941C2 (en) 2008-09-15 2010-05-18 Phasein Ab Gas sampling line for breathing gases
US20100073197A1 (en) * 2008-09-19 2010-03-25 Honeywell International Inc., System and method for acquiring data from an aircraft
US8986208B2 (en) * 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US8597570B2 (en) * 2008-11-04 2013-12-03 Panasonic Corporation Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program
ES2338624B1 (en) * 2008-11-07 2011-09-13 Sabirmedical,S.L. SYSTEM AND APPARATUS FOR NON-INVASIVE MEASUREMENT OF GLUCOSE LEVELS IN BLOOD.
US10437962B2 (en) * 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US9330237B2 (en) * 2008-12-24 2016-05-03 Medtronic Minimed, Inc. Pattern recognition and filtering in a therapy management system
US8771204B2 (en) 2008-12-30 2014-07-08 Masimo Corporation Acoustic sensor assembly
US8560082B2 (en) 2009-01-30 2013-10-15 Abbott Diabetes Care Inc. Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US8588880B2 (en) 2009-02-16 2013-11-19 Masimo Corporation Ear sensor
WO2010099170A1 (en) * 2009-02-27 2010-09-02 Ortho-Clinical Diagnostics, Inc. Method for detecting the impending analytical failure of networked diagnostic clinical analyzers
US10007758B2 (en) 2009-03-04 2018-06-26 Masimo Corporation Medical monitoring system
US9323894B2 (en) 2011-08-19 2016-04-26 Masimo Corporation Health care sanitation monitoring system
US10032002B2 (en) 2009-03-04 2018-07-24 Masimo Corporation Medical monitoring system
WO2010102069A2 (en) 2009-03-04 2010-09-10 Masimo Corporation Medical monitoring system
US8388353B2 (en) 2009-03-11 2013-03-05 Cercacor Laboratories, Inc. Magnetic connector
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
WO2010129375A1 (en) 2009-04-28 2010-11-11 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US8483967B2 (en) 2009-04-29 2013-07-09 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US8571619B2 (en) 2009-05-20 2013-10-29 Masimo Corporation Hemoglobin display and patient treatment
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
EP2440285B1 (en) * 2009-06-10 2021-08-04 Medtronic, Inc. Tissue oxygenation monitoring in heart failure
US9091676B2 (en) 2010-06-09 2015-07-28 Optiscan Biomedical Corp. Systems and methods for measuring multiple analytes in a sample
EP3936032A1 (en) 2009-07-23 2022-01-12 Abbott Diabetes Care, Inc. Real time management of data relating to physiological control of glucose levels
DK3689237T3 (en) 2009-07-23 2021-08-16 Abbott Diabetes Care Inc Method of preparation and system for continuous analyte measurement
US8473020B2 (en) 2009-07-29 2013-06-25 Cercacor Laboratories, Inc. Non-invasive physiological sensor cover
WO2011014851A1 (en) 2009-07-31 2011-02-03 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
WO2011026148A1 (en) * 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
EP3923295A1 (en) 2009-08-31 2021-12-15 Abbott Diabetes Care, Inc. Medical devices and methods
ES2912584T3 (en) 2009-08-31 2022-05-26 Abbott Diabetes Care Inc A glucose monitoring system and method
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US20110137297A1 (en) 2009-09-17 2011-06-09 Kiani Massi Joe E Pharmacological management system
WO2011041531A1 (en) 2009-09-30 2011-04-07 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US20110082711A1 (en) 2009-10-06 2011-04-07 Masimo Laboratories, Inc. Personal digital assistant or organizer for monitoring glucose levels
US9839381B1 (en) 2009-11-24 2017-12-12 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
DE112010004682T5 (en) 2009-12-04 2013-03-28 Masimo Corporation Calibration for multi-level physiological monitors
US9153112B1 (en) 2009-12-21 2015-10-06 Masimo Corporation Modular patient monitor
US11289199B2 (en) 2010-01-19 2022-03-29 Masimo Corporation Wellness analysis system
JP2013521054A (en) 2010-03-01 2013-06-10 マシモ コーポレイション Adaptive alarm system
US8584345B2 (en) 2010-03-08 2013-11-19 Masimo Corporation Reprocessing of a physiological sensor
US9307928B1 (en) 2010-03-30 2016-04-12 Masimo Corporation Plethysmographic respiration processor
US8666468B1 (en) 2010-05-06 2014-03-04 Masimo Corporation Patient monitor for determining microcirculation state
US20110313680A1 (en) * 2010-06-22 2011-12-22 Doyle Iii Francis J Health Monitoring System
JP5710767B2 (en) 2010-09-28 2015-04-30 マシモ コーポレイション Depth of consciousness monitor including oximeter
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US9211095B1 (en) 2010-10-13 2015-12-15 Masimo Corporation Physiological measurement logic engine
US20120226117A1 (en) 2010-12-01 2012-09-06 Lamego Marcelo M Handheld processing device including medical applications for minimally and non invasive glucose measurements
US10332630B2 (en) 2011-02-13 2019-06-25 Masimo Corporation Medical characterization system
US9066666B2 (en) 2011-02-25 2015-06-30 Cercacor Laboratories, Inc. Patient monitor for monitoring microcirculation
CN103619255B (en) 2011-02-28 2016-11-02 雅培糖尿病护理公司 The device that associates with analyte monitoring device, system and method and combine their device
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
DK3575796T3 (en) 2011-04-15 2021-01-18 Dexcom Inc ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION
US9986919B2 (en) 2011-06-21 2018-06-05 Masimo Corporation Patient monitoring system
US9532722B2 (en) 2011-06-21 2017-01-03 Masimo Corporation Patient monitoring system
US11439329B2 (en) 2011-07-13 2022-09-13 Masimo Corporation Multiple measurement mode in a physiological sensor
US9292916B2 (en) * 2011-08-09 2016-03-22 Hid Global Corporation Methods and systems for estimating genetic characteristics from biometric measurements
US9782077B2 (en) 2011-08-17 2017-10-10 Masimo Corporation Modulated physiological sensor
US20160132375A1 (en) * 2011-09-12 2016-05-12 Ortho-Clinical Diagnostics, Inc. Method for detecting the impending analytical failure of networked diagnostic clinical analyzers
US9943269B2 (en) 2011-10-13 2018-04-17 Masimo Corporation System for displaying medical monitoring data
EP3584799B1 (en) 2011-10-13 2022-11-09 Masimo Corporation Medical monitoring hub
US9808188B1 (en) 2011-10-13 2017-11-07 Masimo Corporation Robust fractional saturation determination
US9778079B1 (en) 2011-10-27 2017-10-03 Masimo Corporation Physiological monitor gauge panel
WO2013066873A1 (en) 2011-10-31 2013-05-10 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
WO2013078426A2 (en) 2011-11-25 2013-05-30 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9392945B2 (en) 2012-01-04 2016-07-19 Masimo Corporation Automated CCHD screening and detection
US11172890B2 (en) 2012-01-04 2021-11-16 Masimo Corporation Automated condition screening and detection
US10149616B2 (en) 2012-02-09 2018-12-11 Masimo Corporation Wireless patient monitoring device
US20130231543A1 (en) * 2012-03-05 2013-09-05 Andrea Facchinetti Method to improve safety monitoring in type-1 diabetic patients by detecting in real-time failures of the glucose
JP6159743B2 (en) 2012-03-08 2017-07-05 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Instrument for determining tissue characteristics
EP2845086B1 (en) 2012-03-25 2021-12-22 Masimo Corporation Physiological monitor touchscreen interface
JP6490577B2 (en) 2012-04-17 2019-03-27 マシモ・コーポレイション How to operate a pulse oximeter device
US8949677B1 (en) * 2012-05-23 2015-02-03 Amazon Technologies, Inc. Detecting anomalies in time series data
US10314492B2 (en) * 2013-05-23 2019-06-11 Medibotics Llc Wearable spectroscopic sensor to measure food consumption based on interaction between light and the human body
US9351672B2 (en) 2012-07-16 2016-05-31 Timothy Ruchti Multiplexed pathlength resolved noninvasive analyzer apparatus with stacked filters and method of use thereof
US9766126B2 (en) 2013-07-12 2017-09-19 Zyomed Corp. Dynamic radially controlled light input to a noninvasive analyzer apparatus and method of use thereof
US9585604B2 (en) 2012-07-16 2017-03-07 Zyomed Corp. Multiplexed pathlength resolved noninvasive analyzer apparatus with dynamic optical paths and method of use thereof
US9351671B2 (en) 2012-07-16 2016-05-31 Timothy Ruchti Multiplexed pathlength resolved noninvasive analyzer apparatus and method of use thereof
US9697928B2 (en) 2012-08-01 2017-07-04 Masimo Corporation Automated assembly sensor cable
EP3395252A1 (en) 2012-08-30 2018-10-31 Abbott Diabetes Care, Inc. Dropout detection in continuous analyte monitoring data during data excursions
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US9955937B2 (en) 2012-09-20 2018-05-01 Masimo Corporation Acoustic patient sensor coupler
US9749232B2 (en) 2012-09-20 2017-08-29 Masimo Corporation Intelligent medical network edge router
US9877650B2 (en) 2012-09-20 2018-01-30 Masimo Corporation Physiological monitor with mobile computing device connectivity
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9560996B2 (en) 2012-10-30 2017-02-07 Masimo Corporation Universal medical system
US9787568B2 (en) 2012-11-05 2017-10-10 Cercacor Laboratories, Inc. Physiological test credit method
EP3181048A1 (en) 2012-12-31 2017-06-21 Omni MedSci, Inc. Near-infrared lasers for non-invasive monitoring of glucose, ketones, hba1c, and other blood constituents
US10660526B2 (en) 2012-12-31 2020-05-26 Omni Medsci, Inc. Near-infrared time-of-flight imaging using laser diodes with Bragg reflectors
US9585563B2 (en) 2012-12-31 2017-03-07 Dexcom, Inc. Remote monitoring of analyte measurements
CA2895982A1 (en) 2012-12-31 2014-07-03 Omni Medsci, Inc. Short-wave infrared super-continuum lasers for early detection of dental caries
US9164032B2 (en) 2012-12-31 2015-10-20 Omni Medsci, Inc. Short-wave infrared super-continuum lasers for detecting counterfeit or illicit drugs and pharmaceutical process control
US9730620B2 (en) 2012-12-31 2017-08-15 Dexcom, Inc. Remote monitoring of analyte measurements
WO2014143276A2 (en) 2012-12-31 2014-09-18 Omni Medsci, Inc. Short-wave infrared super-continuum lasers for natural gas leak detection, exploration, and other active remote sensing applications
US9993159B2 (en) 2012-12-31 2018-06-12 Omni Medsci, Inc. Near-infrared super-continuum lasers for early detection of breast and other cancers
US9724025B1 (en) 2013-01-16 2017-08-08 Masimo Corporation Active-pulse blood analysis system
EP3662833A1 (en) * 2013-02-20 2020-06-10 Dexcom, Inc. Retrospective retrofitting method to generate a continuous glucose concentration profile
US9965946B2 (en) 2013-03-13 2018-05-08 Masimo Corporation Systems and methods for monitoring a patient health network
US9445445B2 (en) 2013-03-14 2016-09-13 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US9936917B2 (en) 2013-03-14 2018-04-10 Masimo Laboratories, Inc. Patient monitor placement indicator
EP2972260B1 (en) 2013-03-15 2018-07-11 Roche Diabetes Care GmbH Methods of scaling data used to construct biosensor algorithms
WO2014140173A1 (en) 2013-03-15 2014-09-18 Roche Diagnostics Gmbh Descriptor-based methods of electrochemically measuring an analyte as well as devices, apparatuses and systems incoporating the same
CA2900885C (en) 2013-03-15 2017-12-19 F. Hoffmann-La Roche Ag Methods of electrochemically measuring an analyte with a test sequence having a pulsed dc block as well as devices, apparatuses and systems incorporating the same
WO2014140177A2 (en) 2013-03-15 2014-09-18 Roche Diagnostics Gmbh Methods of detecting high antioxidant levels during electrochemical measurements and failsafing an analyte concentration therefrom as well as devices, apparatuses and systems incorporting the same
PL2972268T3 (en) 2013-03-15 2017-10-31 Hoffmann La Roche Methods of failsafing electrochemical measurements of an analyte as well as devices, apparatuses and systems incorporating the same
JP6352954B2 (en) 2013-03-15 2018-07-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Method and device for using information from recovery pulses in electrochemical analyte measurement, apparatus and system incorporating them
US9891079B2 (en) 2013-07-17 2018-02-13 Masimo Corporation Pulser with double-bearing position encoder for non-invasive physiological monitoring
CA2910596C (en) 2013-07-19 2021-07-20 Dexcom, Inc. Time averaged basal rate optimizer
US10555678B2 (en) 2013-08-05 2020-02-11 Masimo Corporation Blood pressure monitor with valve-chamber assembly
WO2015038683A2 (en) 2013-09-12 2015-03-19 Cercacor Laboratories, Inc. Medical device management system
EP3054849B1 (en) 2013-10-07 2022-03-16 Masimo Corporation Regional oximetry sensor
US11147518B1 (en) 2013-10-07 2021-10-19 Masimo Corporation Regional oximetry signal processor
US10832818B2 (en) 2013-10-11 2020-11-10 Masimo Corporation Alarm notification system
US10279247B2 (en) 2013-12-13 2019-05-07 Masimo Corporation Avatar-incentive healthcare therapy
CA2933166C (en) 2013-12-31 2020-10-27 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US11259745B2 (en) 2014-01-28 2022-03-01 Masimo Corporation Autonomous drug delivery system
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
US10123729B2 (en) 2014-06-13 2018-11-13 Nanthealth, Inc. Alarm fatigue management systems and methods
US10231670B2 (en) 2014-06-19 2019-03-19 Masimo Corporation Proximity sensor in pulse oximeter
US20160029970A1 (en) * 2014-07-31 2016-02-04 Lg Cns Co., Ltd. Apparatus and method for determining validity of biological data
US10111591B2 (en) 2014-08-26 2018-10-30 Nanthealth, Inc. Real-time monitoring systems and methods in a healthcare environment
US10231657B2 (en) 2014-09-04 2019-03-19 Masimo Corporation Total hemoglobin screening sensor
JP6328530B2 (en) * 2014-09-16 2018-05-23 ジーニアルライト株式会社 Blood coagulation detection apparatus, blood coagulation detection method, and blood coagulation detection program
US10383520B2 (en) 2014-09-18 2019-08-20 Masimo Semiconductor, Inc. Enhanced visible near-infrared photodiode and non-invasive physiological sensor
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
WO2016057553A1 (en) 2014-10-07 2016-04-14 Masimo Corporation Modular physiological sensors
KR102335739B1 (en) 2014-12-19 2021-12-06 삼성전자주식회사 Apparatus and method for measuring a blood glucose in a noninvasive manner
US10568553B2 (en) 2015-02-06 2020-02-25 Masimo Corporation Soft boot pulse oximetry sensor
CN107431301B (en) 2015-02-06 2021-03-30 迈心诺公司 Connector assembly with retractable needle for use with medical sensors
EP3253289B1 (en) 2015-02-06 2020-08-05 Masimo Corporation Fold flex circuit for optical probes
US10737024B2 (en) 2015-02-18 2020-08-11 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
CN104665840B (en) * 2015-03-02 2017-11-21 桂林麦迪胜电子科技有限公司 Woundless blood sugar measuring method and finger tip measuring probe
US9427153B1 (en) * 2015-03-11 2016-08-30 Thomas P. Hull Corneal cover and method of use thereof
US10524738B2 (en) 2015-05-04 2020-01-07 Cercacor Laboratories, Inc. Noninvasive sensor system with visual infographic display
US11653862B2 (en) 2015-05-22 2023-05-23 Cercacor Laboratories, Inc. Non-invasive optical physiological differential pathlength sensor
WO2017011346A1 (en) 2015-07-10 2017-01-19 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US10991135B2 (en) 2015-08-11 2021-04-27 Masimo Corporation Medical monitoring analysis and replay including indicia responsive to light attenuated by body tissue
CN108348162B (en) 2015-08-31 2021-07-23 梅西莫股份有限公司 Wireless patient monitoring system and method
IN2015CH04653A (en) * 2015-09-02 2015-09-11 Wipro Ltd
US11504066B1 (en) 2015-09-04 2022-11-22 Cercacor Laboratories, Inc. Low-noise sensor system
US11679579B2 (en) 2015-12-17 2023-06-20 Masimo Corporation Varnish-coated release liner
EP3397140A4 (en) 2015-12-28 2019-08-21 Dexcom, Inc. Systems and methods for remote and host monitoring communications
WO2017123525A1 (en) 2016-01-13 2017-07-20 Bigfoot Biomedical, Inc. User interface for diabetes management system
EP3453414A1 (en) 2016-01-14 2019-03-13 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
CN105725968B (en) * 2016-01-29 2019-02-05 江西智能无限物联科技有限公司 Intelligent skin detector
US10993662B2 (en) 2016-03-04 2021-05-04 Masimo Corporation Nose sensor
US10537285B2 (en) 2016-03-04 2020-01-21 Masimo Corporation Nose sensor
US11209358B2 (en) 2016-03-14 2021-12-28 Analog Devices, Inc. Blocking specular reflections
US20170261427A1 (en) * 2016-03-14 2017-09-14 Analog Devices, Inc. Optical measurements of chemical content
WO2017160766A1 (en) * 2016-03-14 2017-09-21 Analog Devices, Inc. Optical evaluation of skin type and condition
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
CA3133253A1 (en) 2016-03-31 2017-10-05 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US11191484B2 (en) 2016-04-29 2021-12-07 Masimo Corporation Optical sensor tape
US10608817B2 (en) 2016-07-06 2020-03-31 Masimo Corporation Secure and zero knowledge data sharing for cloud applications
US10617302B2 (en) 2016-07-07 2020-04-14 Masimo Corporation Wearable pulse oximeter and respiration monitor
EP3515535A1 (en) 2016-09-23 2019-07-31 Insulet Corporation Fluid delivery device with sensor
WO2018071715A1 (en) 2016-10-13 2018-04-19 Masimo Corporation Systems and methods for patient fall detection
US11504058B1 (en) 2016-12-02 2022-11-22 Masimo Corporation Multi-site noninvasive measurement of a physiological parameter
US10750984B2 (en) 2016-12-22 2020-08-25 Cercacor Laboratories, Inc. Methods and devices for detecting intensity of light with translucent detector
US10721785B2 (en) 2017-01-18 2020-07-21 Masimo Corporation Patient-worn wireless physiological sensor with pairing functionality
WO2018156648A1 (en) 2017-02-24 2018-08-30 Masimo Corporation Managing dynamic licenses for physiological parameters in a patient monitoring environment
WO2018156809A1 (en) 2017-02-24 2018-08-30 Masimo Corporation Augmented reality system for displaying patient data
US11086609B2 (en) 2017-02-24 2021-08-10 Masimo Corporation Medical monitoring hub
US10388120B2 (en) 2017-02-24 2019-08-20 Masimo Corporation Localized projection of audible noises in medical settings
US10327713B2 (en) 2017-02-24 2019-06-25 Masimo Corporation Modular multi-parameter patient monitoring device
EP3585254B1 (en) 2017-02-24 2024-03-20 Masimo Corporation Medical device cable and method of sharing data between connected medical devices
EP3592231A1 (en) 2017-03-10 2020-01-15 Masimo Corporation Pneumonia screener
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
WO2018194992A1 (en) 2017-04-18 2018-10-25 Masimo Corporation Nose sensor
US10918281B2 (en) 2017-04-26 2021-02-16 Masimo Corporation Medical monitoring device having multiple configurations
US10856750B2 (en) 2017-04-28 2020-12-08 Masimo Corporation Spot check measurement system
JP7159208B2 (en) 2017-05-08 2022-10-24 マシモ・コーポレイション A system for pairing a medical system with a network controller by using a dongle
WO2019014629A1 (en) 2017-07-13 2019-01-17 Cercacor Laboratories, Inc. Medical monitoring device for harmonizing physiological measurements
US10637181B2 (en) 2017-08-15 2020-04-28 Masimo Corporation Water resistant connector for noninvasive patient monitor
US11298021B2 (en) 2017-10-19 2022-04-12 Masimo Corporation Medical monitoring system
US20190120785A1 (en) 2017-10-24 2019-04-25 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
USD925597S1 (en) 2017-10-31 2021-07-20 Masimo Corporation Display screen or portion thereof with graphical user interface
JP7282085B2 (en) 2017-10-31 2023-05-26 マシモ・コーポレイション System for displaying oxygen status indicators
CN109995562B (en) * 2017-12-30 2022-11-08 中国移动通信集团河北有限公司 Network traffic prediction method, device, equipment and medium
US11766198B2 (en) 2018-02-02 2023-09-26 Cercacor Laboratories, Inc. Limb-worn patient monitoring device
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
WO2019204368A1 (en) 2018-04-19 2019-10-24 Masimo Corporation Mobile patient alarm display
US11883129B2 (en) 2018-04-24 2024-01-30 Cercacor Laboratories, Inc. Easy insert finger sensor for transmission based spectroscopy sensor
CN112236826A (en) 2018-05-04 2021-01-15 英赛罗公司 Safety constraints for drug delivery systems based on control algorithms
IT201800005918A1 (en) * 2018-05-31 2019-12-01 SYSTEM FOR THE DETECTION OF MALFUNCTIONS IN DEVICES FOR THE ADMINISTRATION OF INSULIN
US10932729B2 (en) 2018-06-06 2021-03-02 Masimo Corporation Opioid overdose monitoring
KR102179203B1 (en) * 2018-07-09 2020-11-16 주식회사 필로시스 Device and method to determine blood glucose sensing data
US10779098B2 (en) 2018-07-10 2020-09-15 Masimo Corporation Patient monitor alarm speaker analyzer
US11872156B2 (en) 2018-08-22 2024-01-16 Masimo Corporation Core body temperature measurement
CA3112209C (en) 2018-09-28 2023-08-29 Insulet Corporation Activity mode for artificial pancreas system
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
CA3115776A1 (en) 2018-10-11 2020-04-16 Masimo Corporation Patient connector assembly with vertical detents
USD999246S1 (en) 2018-10-11 2023-09-19 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD998630S1 (en) 2018-10-11 2023-09-12 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD917550S1 (en) 2018-10-11 2021-04-27 Masimo Corporation Display screen or portion thereof with a graphical user interface
US11406286B2 (en) 2018-10-11 2022-08-09 Masimo Corporation Patient monitoring device with improved user interface
US11389093B2 (en) 2018-10-11 2022-07-19 Masimo Corporation Low noise oximetry cable
USD998631S1 (en) 2018-10-11 2023-09-12 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD916135S1 (en) 2018-10-11 2021-04-13 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD917564S1 (en) 2018-10-11 2021-04-27 Masimo Corporation Display screen or portion thereof with graphical user interface
USD897098S1 (en) 2018-10-12 2020-09-29 Masimo Corporation Card holder set
EP3864869A1 (en) 2018-10-12 2021-08-18 Masimo Corporation System for transmission of sensor data using dual communication protocol
US11464410B2 (en) 2018-10-12 2022-10-11 Masimo Corporation Medical systems and methods
US11684296B2 (en) 2018-12-21 2023-06-27 Cercacor Laboratories, Inc. Noninvasive physiological sensor
JP2022529948A (en) 2019-04-17 2022-06-27 マシモ・コーポレイション Patient monitoring systems, equipment, and methods
KR20200127470A (en) * 2019-05-02 2020-11-11 삼성전자주식회사 Personalized bio-information correction apparatus and method
USD921202S1 (en) 2019-08-16 2021-06-01 Masimo Corporation Holder for a blood pressure device
USD917704S1 (en) 2019-08-16 2021-04-27 Masimo Corporation Patient monitor
USD919100S1 (en) 2019-08-16 2021-05-11 Masimo Corporation Holder for a patient monitor
USD919094S1 (en) 2019-08-16 2021-05-11 Masimo Corporation Blood pressure device
USD985498S1 (en) 2019-08-16 2023-05-09 Masimo Corporation Connector
US11832940B2 (en) 2019-08-27 2023-12-05 Cercacor Laboratories, Inc. Non-invasive medical monitoring device for blood analyte measurements
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
KR20220083771A (en) 2019-10-18 2022-06-20 마시모 코오퍼레이션 Display layouts and interactive objects for patient monitoring
USD927699S1 (en) 2019-10-18 2021-08-10 Masimo Corporation Electrode pad
CN115176155A (en) 2019-10-25 2022-10-11 塞卡科实验室有限公司 Indicator compounds, devices including indicator compounds, and methods of making and using the same
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11879960B2 (en) 2020-02-13 2024-01-23 Masimo Corporation System and method for monitoring clinical activities
EP4104037A1 (en) 2020-02-13 2022-12-21 Masimo Corporation System and method for monitoring clinical activities
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
WO2021166606A1 (en) * 2020-02-20 2021-08-26 テルモ株式会社 Component measuring device, component measuring device set, and information processing method
JPWO2021166470A1 (en) * 2020-02-20 2021-08-26
EP4086613A4 (en) * 2020-02-20 2023-01-25 TERUMO Kabushiki Kaisha Component measurement device, component measurement device set, and information processing method
EP4086627A4 (en) * 2020-02-20 2023-01-04 TERUMO Kabushiki Kaisha Component measurement device, component measurement device set, and information processing method
WO2021166561A1 (en) * 2020-02-20 2021-08-26 テルモ株式会社 Component measurement device, component measurement device set, and information processing method
EP4120901A1 (en) 2020-03-20 2023-01-25 Masimo Corporation Wearable device for noninvasive body temperature measurement
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
USD933232S1 (en) 2020-05-11 2021-10-12 Masimo Corporation Blood pressure monitor
USD979516S1 (en) 2020-05-11 2023-02-28 Masimo Corporation Connector
USD980091S1 (en) 2020-07-27 2023-03-07 Masimo Corporation Wearable temperature measurement device
USD974193S1 (en) 2020-07-27 2023-01-03 Masimo Corporation Wearable temperature measurement device
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
USD946597S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
USD946596S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
USD946598S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
USD997365S1 (en) 2021-06-24 2023-08-29 Masimo Corporation Physiological nose sensor
US11709820B2 (en) * 2021-09-03 2023-07-25 Bank Of America Corporation System for implementing intelligent data analysis
USD1000975S1 (en) 2021-09-22 2023-10-10 Masimo Corporation Wearable temperature measurement device
WO2023049900A1 (en) 2021-09-27 2023-03-30 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
CN115950666B (en) * 2023-03-15 2023-05-30 石家庄市惠源淀粉有限公司 Intelligent fault detection method for starch glucose production equipment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103030D0 (en) * 2001-02-07 2001-03-21 Univ London Spectrum processing and processor

Also Published As

Publication number Publication date
WO2003058191A3 (en) 2004-02-26
US6788965B2 (en) 2004-09-07
WO2003058191A2 (en) 2003-07-17
US20030060692A1 (en) 2003-03-27
AU2002365107A1 (en) 2003-07-24
AU2002365107A8 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
WO2003058191B1 (en) An intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes
US6280381B1 (en) Intelligent system for noninvasive blood analyte prediction
AU754677B2 (en) System and method for noninvasive blood analyte measurements
US6501982B1 (en) System for the noninvasive estimation of relative age
EP1250082B1 (en) Classification and characterization of tissue through features related to adipose tissue
EP1250083B1 (en) Sex determination
JP5047962B2 (en) Method of operating test / diagnosis apparatus for cancer, systemic lupus erythematosus (SLE) or antiphospholipid antibody syndrome using near infrared light
JP2005534428A (en) Near-infrared spectroscopic analysis of blood vessel walls
JP2006126219A (en) Method and apparatus for multi-spectral analysis in noninvasive infrared spectroscopy
US6424859B2 (en) Diagnosis of rheumatoid arthritis in vivo using a novel spectroscopic approach
US20030087456A1 (en) Within-sample variance classification of samples
CN107303174A (en) A kind of internet+spectrum clinical tumor medical diagnostic method
WO2007066589A1 (en) Method and apparatus for examining and diagnosing life style-related disease using near-infrared spectroscopy
US8233960B2 (en) Method and device for diagnosing chronic fatigue syndrome (CFS) by using near infrared spectrum
CN112716447A (en) Oral cancer classification system based on deep learning of Raman detection spectral data
JP2004321325A (en) Method of quantitating blood glucose level
US20230194532A1 (en) Quantum optics profiles for screening, diagnosis, and prognosis of diseases
US20240079093A1 (en) System and method for non-invasive quantification of blood biomarkers
CN116530942A (en) Monitoring device based on spectrum sensor
Cohen et al. Paper Session II-B-Optical Diagnostics: Reagentless Chemistry for Extended Space Flights

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Effective date: 20040112

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP